<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987922</url>
  </required_header>
  <id_info>
    <org_study_id>FI-HUCH-220424</org_study_id>
    <nct_id>NCT00987922</nct_id>
  </id_info>
  <brief_title>Mild Hypothermia in Acute Ischemic Stroke</brief_title>
  <official_title>Mild Hypothermia in Acute Ischemic Stroke After Thrombolytic Therapy: a Prospective,Open,Randomized,Single-center,Safety and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Helsinki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Mild hypothermia using non-invasive temperature management system in a stroke&#xD;
      unit is safe and feasible in spontaneously breathing, alteplase-thrombolyzed patients with&#xD;
      acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fever is associated with higher stroke mortality and poor outcome, but it is yet unknown&#xD;
      whether this association is causative or epiphenomenal.&#xD;
&#xD;
      In temporary brain ischemia rodent models hypothermia results in a significant increase in&#xD;
      the number of surviving neurons and smaller infarction size as measured with histological&#xD;
      examination after death.&#xD;
&#xD;
      Therapeutic effect has been shown in clinical trials in comatose cardiac arrest patients and&#xD;
      newborn infants with perinatal hypoxic-ischemic brain injury.&#xD;
&#xD;
      Design: A prospective, open, randomized single-center study.&#xD;
&#xD;
      Study population: 36 patients, 18-85 years of age presenting with symptoms of acute ischemic&#xD;
      hemispheric stroke with persisting significant neurological deficit (NIHSS 7-20 or NIHSS 2&#xD;
      for dysphasia or NIHSS 3 for paralysis of upper or lower limb) at 2 hours after thrombolysis.&#xD;
&#xD;
      Method: Patients are randomized to hypothermia- or control-group via randomization envelopes.&#xD;
      Patients assigned to receive hypothermia are cooled to a core temperature of 35°C for 12&#xD;
      hours by means of a non-invasive temperature management system and cold i.v. fluids.&#xD;
      Induction of hypothermia is initiated within 6 hours of symptom onset. After 12 hours of&#xD;
      successful cooling the target temperature is gradually raised to achieve slow re-warming of&#xD;
      0.2°C/h until the core temperature reaches 36.8°C.&#xD;
&#xD;
      Patients are breathing spontaneously and shivering is controlled with following medication;&#xD;
      dexmedetomidine 0.2-0.7 µg/kg/h (i.v.), buspirone 5-20 mg x 3 (nasogastric tube), and&#xD;
      meperidine 25mg (i.v.) when needed.&#xD;
&#xD;
      Core temperature, blood pressure (BP), oxygen saturation, ECG and EEG are measured&#xD;
      continuously and registered hourly. Blood tests will be taken before, during and after&#xD;
      hypothermia. Brain CT will be controlled when normothermia is reached, no later than 30 hours&#xD;
      from symptom onset. Brain MRI will be performed 3-7 days from symptom onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients maintaining temperature below 36.0°C 80% of the 12-hour hypothermia period.</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of intracerebral hemorrhage, infections, hemodynamically significant cardiac arrhythmias, severe disturbance of electrolytes and fluid balance, thrombocytopenia, and serious adverse events</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality during acute phase (7 days), 1 month, and 3 month follow-up; and readmission to hospital for any reason within 3-months.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of modified Rankin Scale-responders (mRS 0-2), Barthel Index, NIHSS, Glasgow Outcome Scale</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological tests</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of infarction in MRI, and grading of the possible hemorrhagic transformation according to SITS scale (MRI includes scout images, DWI, T1, T2, FLAIR, T2*, and MR angiography)</measure>
    <time_frame>3-7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Brain Ischemia</condition>
  <arm_group>
    <arm_group_label>Hypothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hypothermia</intervention_name>
    <description>Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C</description>
    <arm_group_label>Hypothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute ischemic hemispheric stroke treated with Actilyse(tPA)-thrombolysis according to&#xD;
             Meilahti protocol&#xD;
&#xD;
          -  NIHSS 7-20 (after thrombolysis) or a significant paresis of arm or leg (NIHSS 3, no&#xD;
             movement against gravity) or a significant dysphasia (NIHSS 2-3) despite of the total&#xD;
             NIHSS score&#xD;
&#xD;
          -  Symptom onset within 6 hour&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Platelet count &lt; 75,000/mm3&#xD;
&#xD;
          -  Known coagulopathy (INR spontaneously &gt;1.5)&#xD;
&#xD;
          -  Hemodynamical unstability&#xD;
&#xD;
          -  Recent history of angina pectoris or acute myocardial infarction&#xD;
&#xD;
          -  Sepsis within 72 hours&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Pre-existing neurological disability with modified Rankin Scale Score&gt;2&#xD;
&#xD;
          -  Known allergy or intolerance to buspirone, dexmedetomidine, meperidine&#xD;
&#xD;
          -  Intracranial hemorrhage in brain CT scan&#xD;
&#xD;
          -  Intracranial mass lesion (i.e., abscess, tumor, or infection)&#xD;
&#xD;
          -  Participation in an other therapy trial within last 3 months&#xD;
&#xD;
          -  Hypothermia- treatment cannot be initiated within 6 hours of symptom onset&#xD;
&#xD;
          -  Protocol violation in thrombolytic therapy&#xD;
&#xD;
          -  Any condition where researchers assume that the patient is not suitable (must be&#xD;
             reasoned)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markku Kaste, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Finland</country>
  </removed_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <last_update_submitted>September 17, 2011</last_update_submitted>
  <last_update_submitted_qc>September 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Helsinki</investigator_affiliation>
    <investigator_full_name>Katja Piironen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Acute</keyword>
  <keyword>Infarction</keyword>
  <keyword>Ischemic</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>Mild</keyword>
  <keyword>Hypothermia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

